SMA Newborn Screening Kits

{
  "id": "031045-2026",
  "tag": [
    "award",
    "contract"
  ],
  "bids": {
    "statistics": [
      {
        "id": "1",
        "value": 1,
        "measure": "bids",
        "relatedLot": "1"
      },
      {
        "id": "2",
        "value": 1,
        "measure": "smeBids",
        "relatedLot": "1"
      },
      {
        "id": "3",
        "value": 1,
        "measure": "foreignBidsFromEU",
        "relatedLot": "1"
      },
      {
        "id": "4",
        "value": 0,
        "measure": "foreignBidsFromNonEU",
        "relatedLot": "1"
      },
      {
        "id": "5",
        "value": 1,
        "measure": "electronicBids",
        "relatedLot": "1"
      }
    ]
  },
  "date": "2026-04-02T15:29:49+01:00",
  "ocid": "ocds-h6vhtk-066e98",
  "buyer": {
    "id": "GB-FTS-3524",
    "name": "NHS Greater Glasgow and Clyde"
  },
  "links": [
    {
      "rel": "canonical",
      "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000826401"
    }
  ],
  "awards": [
    {
      "id": "031045-2026-1",
      "status": "active",
      "suppliers": [
        {
          "id": "GB-FTS-177780",
          "name": "Labsystems Diagnostics OY"
        }
      ],
      "relatedLots": [
        "1"
      ]
    }
  ],
  "tender": {
    "id": "ocds-h6vhtk-066e98",
    "lots": [
      {
        "id": "1",
        "status": "cancelled",
        "hasOptions": false,
        "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee.  NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement to screen died blood spot samples from  newborn babies for Spinal Muscular Atrophy (SMA).\nScotland has begun a 2 year evaluation of SMA screening on behalf of the National Screening Committee to gather data to allow a decision to be made about if SMA screening should be included in the UK Newborn Screening Panel.   SMA is cause by a deletion of the SMN1 gene, but the severity of the disease depends on another gene called SMN2.  SMN2 is present in all babies in various copy numbers, and the lower the copy number the more severe the disease.",
        "awardCriteria": {
          "criteria": [
            {
              "name": "Quality",
              "type": "quality",
              "description": "99"
            },
            {
              "type": "price",
              "description": "1"
            }
          ]
        }
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryAddresses": [
          {
            "region": "UKM82"
          }
        ],
        "additionalClassifications": [
          {
            "id": "33696500",
            "scheme": "CPV",
            "description": "Laboratory reagents"
          }
        ]
      }
    ],
    "title": "SMA Newborn Screening Kits",
    "status": "complete",
    "coveredBy": [
      "GPA"
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee.  NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from  newborn babies for Spinal Muscular Atrophy (SMA).",
    "classification": {
      "id": "33696500",
      "scheme": "CPV",
      "description": "Laboratory reagents"
    },
    "procurementMethod": "limited",
    "mainProcurementCategory": "goods",
    "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
    "procurementMethodRationale": "In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "D_OUTSIDE_SCOPE",
        "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
        "description": "The procurement falls outside the scope of application of the directive"
      }
    ]
  },
  "parties": [
    {
      "id": "GB-FTS-3524",
      "name": "NHS Greater Glasgow and Clyde",
      "roles": [
        "buyer",
        "centralPurchasingBody"
      ],
      "address": {
        "region": "UKM82",
        "locality": "Glasgow",
        "postalCode": "G4 0SF",
        "countryName": "United Kingdom",
        "streetAddress": "Procurement Department, Glasgow Royal Infirmary, 84 Castle Street"
      },
      "details": {
        "url": "http://www.nhsggc.scot/about-us/procurement/",
        "buyerProfile": "https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA10722",
        "classifications": [
          {
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE",
            "description": "Body governed by public law"
          },
          {
            "id": "07",
            "scheme": "COFOG",
            "description": "Health"
          }
        ]
      },
      "identifier": {
        "legalName": "NHS Greater Glasgow and Clyde"
      },
      "contactPoint": {
        "email": "william.cullen@nhs.scot",
        "telephone": "+44 1412015388"
      }
    },
    {
      "id": "GB-FTS-177780",
      "name": "Labsystems Diagnostics OY",
      "roles": [
        "supplier"
      ],
      "address": {
        "region": "FI1B",
        "locality": "Vantaa",
        "postalCode": "01720",
        "countryName": "Finland",
        "streetAddress": "Tiilitie 3, Finlandia"
      },
      "details": {
        "scale": "sme"
      },
      "identifier": {
        "legalName": "Labsystems Diagnostics OY"
      },
      "contactPoint": {
        "email": "sales@ladsystemsdx.com",
        "telephone": "+44 358201557530"
      }
    },
    {
      "id": "GB-FTS-3515",
      "name": "Glasgow Sheriff Court",
      "roles": [
        "reviewBody"
      ],
      "address": {
        "locality": "Glasgow",
        "postalCode": "G5 9DA",
        "countryName": "United Kingdom",
        "streetAddress": "PO Box 23, 1 Carlton Place"
      },
      "identifier": {
        "legalName": "Glasgow Sheriff Court"
      }
    }
  ],
  "language": "en",
  "contracts": [
    {
      "id": "031045-2026-1",
      "value": {
        "amount": 237847,
        "currency": "GBP"
      },
      "status": "active",
      "awardID": "031045-2026-1",
      "dateSigned": "2026-03-05T00:00:00Z"
    }
  ],
  "description": "No other commercial kits for SMA screening include the SMN2 copy number.  The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.\n(SC Ref:828095)",
  "initiationType": "tender"
}

{
  "id": "025039-2026",
  "tag": [
    "award",
    "contract"
  ],
  "date": "2026-03-19T10:53:59Z",
  "ocid": "ocds-h6vhtk-066e98",
  "buyer": {
    "id": "GB-FTS-3524",
    "name": "NHS Greater Glasgow and Clyde"
  },
  "links": [
    {
      "rel": "canonical",
      "href": "https://api.publiccontractsscotland.gov.uk/v1/Notice?id=ocds-r6ebe6-0000826401"
    }
  ],
  "awards": [
    {
      "id": "025039-2026-1",
      "status": "active",
      "suppliers": [
        {
          "id": "GB-FTS-177780",
          "name": "Labsystems Diagnostics OY"
        }
      ],
      "relatedLots": [
        "1"
      ]
    }
  ],
  "tender": {
    "id": "ocds-h6vhtk-066e98",
    "lots": [
      {
        "id": "1",
        "hasOptions": false,
        "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee.  NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement to screen died blood spot samples from  newborn babies for Spinal Muscular Atrophy (SMA).\nScotland has begun a 2 year evaluation of SMA screening on behalf of the National Screening Committee to gather data to allow a decision to be made about if SMA screening should be included in the UK Newborn Screening Panel.   SMA is cause by a deletion of the SMN1 gene, but the severity of the disease depends on another gene called SMN2.  SMN2 is present in all babies in various copy numbers, and the lower the copy number the more severe the disease. Additional information: 300 kits required across a 24 month period, with 25 kits to be shipped every 8 weeks, depending on the demand of the service."
      }
    ],
    "items": [
      {
        "id": "1",
        "relatedLot": "1",
        "deliveryAddresses": [
          {
            "region": "UKM82"
          }
        ],
        "additionalClassifications": [
          {
            "id": "33696500",
            "scheme": "CPV",
            "description": "Laboratory reagents"
          }
        ]
      }
    ],
    "title": "SMA Newborn Screening Kits",
    "status": "complete",
    "coveredBy": [
      "GPA"
    ],
    "legalBasis": {
      "id": "32014L0024",
      "scheme": "CELEX"
    },
    "description": "The Scottish Newborn Screening Laboratory has been commissioned to participate in the in-service evaluation for Spinal Muscular Atrophy (SMA) organised by the National Screening Committee.  NHSGG&C require newborn screening kits that measure both SMN1 and SMN2 genes simultaneously. The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol. The requirement is to screen dried blood spot samples from  newborn babies for Spinal Muscular Atrophy (SMA).",
    "classification": {
      "id": "33696500",
      "scheme": "CPV",
      "description": "Laboratory reagents"
    },
    "procurementMethod": "limited",
    "mainProcurementCategory": "goods",
    "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
    "procurementMethodRationale": "In order to award this contract compliantly, NHSGGC will follow Regulation 33. (b)where the works, supplies or services can be supplied only by a particular economic operator for any of the following reasons (ii)competition is absent for technical reasons.\nThere are several commercial kits available for screening for SMA.  This means if an alternative kit is used, SMA can be detected but not the variability or severity of this disease.\nThe screening pathway established in Scotland by clinicians includes measurement of SMN1 and also measurement of SMN2 copy numbers.  Therefore, to allow the laboratory to fulfil the Scottish screening pathway, SMN2 copy numbers must be measured in addition to the SMN1 deletion.  The only identified solution is the proposed awarded kit.\nThis adheres to the recommended screening pathway in Scotland.\nThe benefit to the patient is that the full severity of the disease will be known at the initial appointment with the clinical team.   In traditional pathways the patient will have to wait for diagnostic testing.   Patients with the most severe forms of SMA have very severe symptoms caused by muscle wastage.  This results in reduced movement, often resulting in an inability to sit or walk,  and the need for breathing and feeding tubes.  If the baby is able to start treatment before these symptoms present, they will likely never develop these symptoms.  By knowing the severity of the disease as early as possible, gives the best chance for treatment to be given pre-symptomatically, thus reducing the morbidity and morality associated with this disease.   In addition to this, there is significant  published evidence to show that having the disease severity known at the initial appointment reduces anxiety for the family.\nNo other commercial kits for SMA screening include the SMN2 copy number.  The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.",
    "procurementMethodRationaleClassifications": [
      {
        "id": "D_OUTSIDE_SCOPE",
        "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
        "description": "The procurement falls outside the scope of application of the directive"
      }
    ]
  },
  "parties": [
    {
      "id": "GB-FTS-3524",
      "name": "NHS Greater Glasgow and Clyde",
      "roles": [
        "buyer"
      ],
      "address": {
        "region": "UKM82",
        "locality": "Glasgow",
        "postalCode": "G4 0SF",
        "countryName": "United Kingdom",
        "streetAddress": "Procurement Department, Glasgow Royal Infirmary, 84 Castle Street"
      },
      "details": {
        "url": "http://www.nhsggc.scot/about-us/procurement/",
        "buyerProfile": "https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA10722",
        "classifications": [
          {
            "id": "BODY_PUBLIC",
            "scheme": "TED_CA_TYPE",
            "description": "Body governed by public law"
          },
          {
            "id": "07",
            "scheme": "COFOG",
            "description": "Health"
          }
        ]
      },
      "identifier": {
        "legalName": "NHS Greater Glasgow and Clyde"
      },
      "contactPoint": {
        "email": "william.cullen@nhs.scot",
        "telephone": "+44 1412015388"
      }
    },
    {
      "id": "GB-FTS-177780",
      "name": "Labsystems Diagnostics OY",
      "roles": [
        "supplier"
      ],
      "address": {
        "region": "FI1B",
        "locality": "Vantaa",
        "postalCode": "01720",
        "countryName": "Finland",
        "streetAddress": "Tiilitie 3, Finlandia"
      },
      "details": {
        "scale": "sme"
      },
      "identifier": {
        "legalName": "Labsystems Diagnostics OY"
      },
      "contactPoint": {
        "email": "sales@ladsystemsdx.com",
        "telephone": "+44 358201557530"
      }
    },
    {
      "id": "GB-FTS-3515",
      "name": "Glasgow Sheriff Court",
      "roles": [
        "reviewBody"
      ],
      "address": {
        "locality": "Glasgow",
        "postalCode": "G5 9DA",
        "countryName": "United Kingdom",
        "streetAddress": "PO Box 23, 1 Carlton Place"
      },
      "identifier": {
        "legalName": "Glasgow Sheriff Court"
      }
    }
  ],
  "language": "en",
  "contracts": [
    {
      "id": "025039-2026-1",
      "value": {
        "amount": 237847,
        "currency": "GBP"
      },
      "status": "active",
      "awardID": "025039-2026-1",
      "dateSigned": "2026-03-05T00:00:00Z"
    }
  ],
  "description": "No other commercial kits for SMA screening include the SMN2 copy number.  The SMN2 copy number must be screened for at the same time as the SMN1 deletion in keeping with the Scottish screening protocol.\nNOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=826401.\n(SC Ref:826401)",
  "initiationType": "tender"
}